Iselin NJ, February 17, 2011 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2010. These results are included in the Company’s Yearly Report on Form 10-K which has been filed with the SEC. Fourth Quarter Ended December 31, 2010 The Company recorded a net loss of $152,000, or $0.00 per share, for the fourth quarter […]
Iselin NJ, October 27, 2010 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the third quarter and nine-month period ended September 30, 2010. These results are included in the Company’s Quarterly Report on Form 10-Q which has been filed with the SEC. During the quarter the Company kept expenses to a minimum level while pursuing potential partners for Dextofisopam, its drug for irritable bowel […]
Iselin NJ, August 4, 2010 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the second quarter and six-month period ended June 30, 2010. These results are included in the Company’s Quarterly Report on Form 10-Q which has been filed with the SEC. During the quarter the Company kept expenses to a minimum level while pursuing potential partners for Dextofisopam, its drug for irritable bowel […]
Iselin NJ, May 12, 2010 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the first quarter ended March 31, 2010. The Company recorded a net loss of $0.5 million, or $0.01 per share, for the first quarter 2010 compared to a net loss of $3.7 million, or $0.14 per share, in the first quarter 2009. Research & development expenses decreased by $1,891,425 or 94% […]
Iselin NJ, February 22, 2010 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2009. Fourth Quarter Ended December 31, 2009 Pharmos has no revenues at this time. The fourth quarter net income is partly due to a renegotiated milestone requirement that is not expected to be met and the resulting reversal of a previously recorded […]
Iselin, NJ, November 12, 2009 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the third quarter and nine-month period ended September 30, 2009. Third Quarter Ended September 30, 2009 The Company recorded a net loss of $1.4 million, or $0.02 per share, for the third quarter 2009 compared to a net loss of $2.8 million, or $0.11 per share, in the third quarter 2008. […]
Iselin NJ, October 21, 2009 – Pharmos Corporation (OTCBB – PARS.PK); on September 14, 2009, Pharmos announced the results of its Phase 2b Dextofisopam trial for the treatment of diarrhea predominant and alternating diarrhea and constipation irritable bowel syndrome. While the results did not achieve statistical significance for the primary endpoint of overall adequate relief due to an unexpectedly high placebo response rate, the drug clearly […]
Primary Endpoint was not Achieved, but the 200 mg Treatment Group Demonstrated Activity and was Similar to Previous Phase 2a Successful Results Trial Evaluated Safety and Efficacy of Dextofisopam, a Novel First in-Class Compound Iselin NJ, September 14, 2009 – Pharmos Corporation (OTCBB: PARS.PK) announced today the results of its Phase 2b Dextofisopam clinical trial to evaluate safety and efficacy of the compound in irritable bowel […]
Iselin NJ, August 12, 2009 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the second quarter and six-month period ended June 30, 2009. Second Quarter Ended June 30, 2009 The Company recorded a net loss of $2.3 million, or $0.05 per share, for the second quarter 2009 compared to a net loss of $2.7 million, or $0.10 per share, in the second quarter 2008. […]
Iselin NJ, May 12, 2009 – Pharmos Corporation (OTCBB – PARS.PK) today reported results for the first quarter ended March 31, 2009. The Company recorded a net loss of $3.7 million, or $0.14 per share, for the first quarter 2009 compared to a net loss of $3.6 million, or $0.14 per share, in the first quarter 2008. Cash and short-term investments totaled $2.9 million at March […]